AXIMÂ® Biotech Signs Exclusive Distribution Agreement With Israelâs Rafa Pharmaceuticals
RAFA to Distribute Aximâs Award-Winning Cannabinoid Chewing Gum CanChewÂ®
NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) — AXIMÂ® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, today announced that it has signed an exclusive distribution agreement with Israel-based Rafa Laboratories, Ltd. for distribution of its award-winning cannabinoid chewing gum CanChew.Â®
Under terms of the agreement, Rafa will submit AXIMÂ® Biotechâs CanChewÂ® to the Israeli Ministry of Health to be registered as a nutraceutical in the Country, and will market and distribute the product throughout Israel beginning in 2017. In addition, once AXIMÂ® Biotechâs patented pharmaceutical chewing gum MedChew Rxâ¢, which is currently in clinical trials for registration as a drug for patients suffering from pain and/or spasticity associated with MS, is approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), Rafa will submit it to be registered as a Rx drug product in Israel, and will market and distribute the product throughout the Country.
âWe are pleased to have Rafa as our partner, and our distribution agreement represents an important step to enable expanded market access to our unique, cannabinoid-based products,â said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIMÂ® Biotechnologies. âRafa has a 79-year history as a trusted partner to some of the worldâs leading pharmaceutical companies, and we believe the Company maintains our goal to have a lasting impact on individualsâ well-being. Distribution agreements such as this one with Rafa are steps forward for AXIM to change the healthcare landscape by introducing our proprietary cannabinoid products to pharmaceutical and retail consumer markets worldwide.â
The founders and officers of AXIMÂ® Biotech are the inventors of CanChewÂ®, the worldâs first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of cannabidiol (CBD). AXIMÂ® Biotech holds the exclusive rights to market and distribute CanChewÂ® Gum globally. CanChewÂ® is a hemp CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the CanChewÂ® website include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
In addition, AXIMÂ® Biotech created a pharmaceutical breakthrough invention with the worldâs first patented cannabinoid controlled-release CBD/THC (cannabidiol/
Another AXIMÂ® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis. AXIMÂ® Biotechâs core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinsonâs disease, Alzheimerâs disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohnâs disease.
AXIMÂ® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIMÂ® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell, and distribute hemp-based products.
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P.Â 888-829-0070 email@example.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227